To address that, recent clinical researchers have shown that NSCLC patients with acquired MET amplification may benefit from MET-TKIs including crizotinib (7), capmatinib (8), savolitinib (9), and tepotinib (10). This evidence concerns the gene MET and non-small cell lung carcinoma.